“The current problem has exposed some structural weaknesses from the EU’s medicines supply chain along with a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She proposed that supply chain problems be dealt with within an EU pharmaceutical tactic ant